还原型谷胱甘肽(GSH)针剂对酒精性肝病的疗效和安全性

Efficacy and safety of reduced glutathione(GSH)injection in alcoholic liver disease

目的分析研究还原型谷胱甘肽(GSH)针剂对酒精性肝病的疗效和安全性。方法选取2017年2月至2018年3月在本院接受治疗的酒精性肝病患者92例,依据单双号分法分为对照组和观察组,各46例。对照组患者开展常规治疗(维生素C、门洞氨酸钾美以及甘利欣),观察组患者在对照组基础上联用GSH针剂进行治疗。比较两组患者的生化指标,分析两组患者的临床疗效以及不良反应发生情况。结果治疗前两组患者的生化指标比较,差异无统计学意义;治疗后两组患者的各项生化指标均较治疗前明显改善,且观察组患者的各项指标改善水平优于对照组(P<0.05);观察组患者的临床总改善率明显高于对照组(P<0.05);两组患者在治疗期间均未发生严重不良反应。结论GSH针剂治疗酒精性肝病具有理想的临床疗效。

Objective To analyze the efficacy and safety of reduced glutathione(GSH)injection for alcoholic liver disease.Methods From February 2017 to March 2018,92 patients with alcoholic liver disease who were treated in our hospital were selected.They were divided into control group and observation group according to single and double number grouping,with 46 cases in each group.The control group underwent conventional treatment(vitamin C,ketamine,and ganlixin),and the observation group were treated with GSH injection on the basis of control group.The biochemical indexes of the two groups were compared,and the clinical efficacy and adverse reactions of the two groups were analyzed.Results There was no significant difference in biochemical indicators between the two groups of patients before treatment.After treatment,the biochemical parameters of the two groups of patients were significantly improved compared with before treatment,and the improvement of various indicators of the observation group was higher than the control group(P<0.05).The overall clinical improvement rate of patients in the observation group was significantly higher than that in the control group(P<0.05).No serious adverse reactions occurred during the treatment in both groups.Conclusion GSH injection has good clinical effect in the treatment of alcoholic liver disease.